Innovent Biologics (SEHK:1801) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

1801 주식 개요

바이오 제약 회사인 Innovent Biologics는 중화인민공화국에서 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야에서 단일 클론 항체 및 기타 약물 자산을 개발 및 상업화하는 회사입니다.

1801 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	5/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 44.6% 에서 거래

수익은 매년 50.81% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 27.1% 증가했습니다.

분석가들은 주가가 48.6% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

Innovent Biologics, Inc. 경쟁사

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$39.0b

RemeGen

SEHK:9995

HK$22.8b

3SBio

SEHK:1530

HK$14.5b

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Innovent Biologics
과거 주가
현재 주가	HK$37.15
52주 최고치	HK$49.80
52주 최저치	HK$27.30
베타	0.14
11개월 변경	-2.75%
3개월 변경 사항	3.19%
1년 변경 사항	18.12%
33년 변화	-59.49%
5년 변화	42.34%
IPO 이후 변화	124.07%

최근 뉴스 및 업데이트

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27

주주 수익률

	1801	HK Biotechs	HK 마켓
7D	2.5%	1.8%	2.7%
1Y	18.1%	-34.3%	2.1%

수익률 대 산업: 1801 지난 1년 동안 -34.3 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 1801 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장을 초과했습니다.

가격 변동성

Is 1801's price volatile compared to industry and market?
1801 volatility
1801 Average Weekly Movement	6.8%
Biotechs Industry Average Movement	8.8%
Market Average Movement	7.2%
10% most volatile stocks in HK Market	15.3%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 1801 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 1801 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2011	4,872	Michael Yu	www.innoventbio.com

중화인민공화국에서 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야에서 단일 클론 항체 및 기타 약물 자산을 개발 및 상용화하는 바이오 제약 회사인 Innovent Biologics는 중국 내 종양학, 안과, 자가 면역, 심혈관 및 대사 질환 분야의 전문 제약 회사입니다. 이 회사는 인간 항 PD-1 단일클론항체 타이비트, 완전 인간 항 VEGF 단일클론항체 바이바스다, 재조합 키메라 쥐/인간 항 CD20 단일클론항체 할프리자 등을 제공합니다; 완전 인간 항-TNF-a 단일클론 항체인 설리노(SULINNO), 선택적 FGFR 억제제인 페마자이어(Pemazyre), 새로운 BCR-ABL TK인 올버렘바티닙(Olverembatinib), VEGF 수용체 2 길항제인 사이람자(Cyramza), 선택적이고 강력한 RET 키나제 억제제인 레세브모(Retsevmo) 등이 개발되고 있습니다. 또한 회사는 완전 인간 BCMA CAR T 세포 치료제인 IBI-326, 경구용 PI3Kd 억제제인 IBI-376, KRASG12C 억제제인 IBI-351, 1/TRK 티로신 키나제 억제제인 IBI-344, CEACAM5 표적 ADC인 IBI-126을 개발 중입니다; 새로운 항단백질 전환효소 서브틸리신/켁신 9형 효소 단일클론 항체인 IBI-306, 글루카곤 유사 펩타이드-1 수용체/글루카곤 수용체 이중 작용제인 IBI-362, 새로운 지속성 항 IL-23인 IBI-112를 개발 중입니다.

Innovent Biologics, Inc. 기본 사항 요약

Innovent Biologics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
1801 기본 통계
시가총액	HK$60.48b
수익(TTM)	-HK$1.10b
수익(TTM)	HK$6.67b

9.1x

P/S 비율

-54.7x

P/E 비율

1801 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
1801 손익 계산서(TTM)
수익	CN¥6.21b
수익 비용	CN¥1.81b
총 이익	CN¥4.40b
기타 비용	CN¥5.43b
수익	-CN¥1.03b

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.63
총 마진	70.89%
순이익 마진	-16.56%
부채/자본 비율	28.1%

1801 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

1801 주식 개요

보상

위험 분석

Innovent Biologics, Inc. 경쟁사

SEHK:6990

HK$39.0b

SEHK:9995

HK$22.8b

SEHK:1530

HK$14.5b

SEHK:6826

HK$14.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Now 20% undervalued

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Now 25% undervalued after recent price drop

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Now 20% undervalued

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

First half 2023 earnings: EPS and revenues exceed analyst expectations

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Now 22% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib